Poruk et al. found the clinical utility of serological levels of osteopontin and tissue inhibitor metalloproteinase 1 (TIMP1) in differentiating patients with chronic pancreatitis, pancreatic adenocarcinoma of different stages, and no pancreatic disease in 200 patients. Here, SPP1 is linked to pancreatic adenocarcinoma.